Samsung BioLogics gauges demand for IPO

South Korea’s biggest conglomerate sets out with ambitious plans to raise as much as $2 billion from the listing of its contract drug unit on the Korean stock market.
Samsung BioLogics CEO Kim Tae Han
Samsung BioLogics CEO Kim Tae Han

Samsung BioLogics began pre-deal investor education in Seoul on Tuesday for a $1.7 billion to $2 billion initial public offering that will tempt investors with the prospect of a new behemoth and potential industry disrupter from one of the world’s most successful tech companies.

And they will need to believe in the company’s scalability and growth potential given the extremely aggressive valuation attached to the deal, which is being marketed at 96 times 2015 sales at the top end of the indicative price range. By contrast, Amazon went public in 1997 on a 29 times trailing multiple.

Samsung BioLogics represents Samsung Group’s...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222